💊
ChondroCelect
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Choroby chrząstki
🚫 Wycofano
Terapia zaawansowana
✅
Brak aktywnych alertów
Ten lek nie jest objęty bieżącymi niedoborami, listami ostrzegawczymi ani wycofany z rynku.
Do czego to służy
Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults. Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present. Demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of Chondrocelect in patients with lesions between 1 and 5 cm².
⚠️ Bezpieczeństwo pacjenta
No
Oficjalna strona EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/chondrocelect